MAM
SYRE icon

Martingale Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Martingale Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Sell
4,425
-4,655
-51% -$340K 0.01% 701
2026
Q1 		$458K Buy
9,080
+2,150
+31% +$81.1K 0.01% 662
2025
Q4 		$227K Buy
+6,930
New +$181K 0.01% 735

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Martingale Asset Management's SYRE Position: Q2 2026 in Review

Martingale Asset Management reduced its Spyre Therapeutics (SYRE) stake by 51% in Q2 2026, selling an estimated $340K and leaving 4,425 shares worth $393K. The position accounts for 0.01% of the portfolio, ranked #701.

Martingale Asset Management first reported a position in SYRE in Q4 2025 and has held it in 3 quarters since. The position peaked at $458K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Martingale Asset Management held 4,425 shares of Spyre Therapeutics worth $393K as of Q2 2026.
  • Martingale Asset Management sold 4,655 Spyre Therapeutics shares in Q2 2026, an estimated $340K.
  • Spyre Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #701 holding.
  • Martingale Asset Management first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Martingale Asset Management's Spyre Therapeutics position peaked at $458K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.